Korsana Biosciences, Inc. (KRSA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $30.11
- As of
Kresmion compiles this page from KRSA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Korsana Biosciences, Inc. (KRSA): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-11.
See the full KRSA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for KRSA on one page. Preview it with sample data, then open it live with a free account.
Preview the KRSA dossierActive events for KRSA
No recent events on KRSA in the last 180 days.
FREE, NO ACCOUNT
Every event on KRSA, as it fires
New filings, 13F moves and cross asset events on KRSA land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in KRSA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 23255M204 · 2026Q2 | $203K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, KRSA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
KRSA against its peers
KRSA's operating margin of -239.8% ranks in the 32nd percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | KRSA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.1M USD | 178M USD | 14 | 10 |
| Operating margin | -239.8% | -96.6% | 32 | 10 |
| Net margin | -170.1% | -112.6% | 32 | 10 |
| Return on equity | -38.8% | -44.1% | 59 | 15 |
Peers (20): TSHA, DMRA, GHRS, LBRX, SNDX, TYRA, ANAB, REPL, DRTS, SLN, VOR, FBRX.D, URGN, IMCR, IMTX, RARE, CMPS, NVAX, JANX, STOK. Left out: AAPG (period gap), KALV.D (no annual filing), LYCA (no annual filing), KARD (no annual filing), AVLN (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (KRSA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow KRSA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to KRSA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.